Impact Partnership Wealth LLC Invests $611,000 in Pfizer Inc. $PFE

Impact Partnership Wealth LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 23,999 shares of the biopharmaceutical company’s stock, valued at approximately $611,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Curio Wealth LLC grew its position in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the period. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer during the 2nd quarter worth about $29,000. Grey Fox Wealth Advisors LLC purchased a new stake in Pfizer during the third quarter worth approximately $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer in the second quarter worth $30,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Morgan Stanley decreased their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. UBS Group began coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price on the stock. Finally, TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.06.

Pfizer Price Performance

NYSE PFE opened at $26.43 on Friday. The company has a 50-day moving average price of $25.52 and a two-hundred day moving average price of $25.03. The stock has a market cap of $150.24 billion, a price-to-earnings ratio of 15.36 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla is doubling down on oncology with a roughly $23 billion post?COVID investment plan, positioning Pfizer as a major growth bet on cancer therapies — a strategic pivot investors see as a multi?year revenue driver. ‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post?COVID bet on oncology
• Positive Sentiment: Pfizer struck a non?exclusive licensing agreement to access Novavax’s Matrix?M adjuvant technology (reported value ~$530M), which could boost future vaccine efficacy and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix?M Adjuvant Technology
• Positive Sentiment: A bullish technical/forecast note projects upside toward ~$36.16, which can attract momentum and speculative buying. PFIZER Stock Holds Near $25.86 as Forecast Targets $36.16 Upside
• Neutral Sentiment: Pfizer is due to report Q4 and full?year 2025 results before the market opens Feb. 3; consensus Q4 estimates cited are ~$16.9B sales and $0.57 EPS — the upcoming print is the near?term catalyst. Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
• Neutral Sentiment: Zacks and other outlets report heightened retail/investor attention on PFE and provide deeper metric estimates ahead of earnings — increased search/coverage can amplify moves on the print. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Background pieces (portfolio company lists, Wall Street metric breakdowns) add context but are unlikely to move the stock materially on their own. 7 Companies Owned by Pfizer
• Negative Sentiment: Critical commentary warns of valuation and execution risks (Seeking Alpha: “Buyer Beware”) and highlights that risks may outweigh near?term rewards, which can pressure sentiment. Pfizer: Buyer Beware, The Risk Outweighs The Reward
• Negative Sentiment: Media coverage of past management tactics (CEO comments on extreme COVID-era measures) and notes that PFE has recently underperformed peers may feed governance/PR concerns and short?term selling. Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19 Pfizer Inc. stock underperforms Wednesday when compared to competitors

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.